Major depressive disorder (MDD) is a highly prevalent and disabling mental illness affecting more than 350 million people globally as theleading cause of disability worldwide
Major depressive disorder (MDD) is a leading cause of disability worldwide [1]. Actions to reduce the impact of depression on patients, families and healthcare systems
Current prescribing practices for major depressive disorder (MDD) produce limited treatment success. Although pharmacogenomics may improve outcomes by identifying genetically inappropriate medications, studies to date
Geriatric depression, which affects approximately 5% of older adults (age ≥65 years) in the United States,1,2 places substantial burdens on function, quality of life, and
To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions for
Antidepressants are recommended for use in the treatment of moderate-to-severe major depression [1], but many patients fail to benefit from these medications. Between 30 and
